Crowell & Moring and Faber Daeufer & Itrato Team Up for Life Sciences Counsel
A Stronger Force in Life Sciences Legal Guidance
In a significant development for the life sciences industry, Crowell & Moring LLP has announced its merger with Faber Daeufer & Itrato PC. This strategic alliance aims to provide comprehensive legal support across transactional, regulatory, and litigation domains within the life sciences sector. The combined strengths of these two firms promise to offer a robust suite of services for companies, academic institutions, and investors involved in this rapidly evolving field.
Unparalleled Expertise and Experience
The merger brings together Faber’s impressive track record in venture finance and research & development transactional practices with Crowell’s established strengths in regulatory compliance, government contracting, and intellectual property law. This unification is expected to result in a powerhouse entity capable of navigating the intricate landscape of life sciences legal needs.
Philip T. Inglima, chair of Crowell’s management board, emphasized the importance of this merger: “Companies across the life sciences ecosystem face both substantial opportunities for growth and significant challenges. With our combined expertise, we aim to provide our clients with the necessary guidance to achieve their business objectives.”
Addressing Client Needs in a Dynamic Environment
The range of services offered will be particularly beneficial to clients involved at various stages of life sciences innovation—from startups to established entities. The Faber team, renowned for its firsthand experience in biopharma and contract research, brings a wealth of practical knowledge. They have previously advised over 2,500 clients on a plethora of transactions including mergers, licensing agreements, and other strategic collaborations.
With the complexities introduced by new regulatory frameworks, compliance issues, and geopolitical factors, clients can anticipate a tailored approach to their unique challenges. Joseph L. Faber, founder of Faber Daeufer, highlighted that this merger strategically positions them to better support clients, especially those engaging with global investors and partners.
A Nationwide and Global Impact
In a move to strengthen its footprint, Crowell will establish a new office in Boston, leveraging Faber’s longstanding presence in the area—a notable hub for life sciences innovation. Additional offices in New York, San Francisco, and London will enhance their capacity to serve clients in key markets both in the United States and Europe.
Stephen J. McBrady, a member of Crowell's Executive Committee, remarked, “Opening an office in Boston is a strategic response to our growing client base and the increasing demand within this vibrant community.”
Supporting Diverse Stakeholders
The newly formed Crowell Life Sciences group will cater to a diverse set of clientele, including academic research institutions, NGOs, and investment firms involved in the development of groundbreaking therapeutics and medical devices, often enhanced by artificial intelligence and other technological advancements. They are poised to offer not only legal advice but also strategic insights that could drive innovation and investment in the sector.
Looking to the Future
As the life sciences sector continues to grow and evolve, the partnership between Crowell & Moring and Faber Daeufer & Itrato stands as a beacon of support for stakeholders navigating this complex environment. The aim is to offer an integrated, solution-oriented approach that addresses not just legal needs, but also the broader challenges of operating in a competitive and dynamic landscape.
For more information about Crowell Life Sciences, please visit their official website.